

EASDec 2015



25th ANNUAL MEETING

26th - 27th - 28th JUNE 2015

TORINO

Cavallerizza Reale

Via Giuseppe Verdi, 9

CONTENTS

- 2** Welcome
- 3** About EASDec
- 4** Symposium 1&2
- 5** Sessions 1&2
- 6** Session 3
- 10** Session 4
- 11** Sessions 5&6
- 12** Location&Social events
- 13** Sponsors
- 17** Local Scientific Committee
- 22** EASDec 2016



WELCOME



Dear Friends,

This is a special occasion because we celebrate 25 years of EASDec. Time flies! The study group on Eye Complications of the EASD was established by some enthusiastic pioneers of the fight against diabetes-related blindness: Eva Kohner, José Cunha-Vaz, Gaetano Crepaldi, Carl-David and Elisabet Agardh, Anne Kathrin Sjoelie, Einar Stefansson, and others. Although, sadly, some of them are no longer physically among us, we feel that all of them are here to celebrate progress achieved over one quarter of century. So much and yet so little has been done: laser treatment was being standardised 25 years ago and little could be done for macular edema. Cataract extraction was still a somewhat adventurous procedure and vitrectomies were

bordering on science fiction. Screening was almost a dirty word in some circles!

But so much is left to do: establish what closes capillaries and makes them leak and grow, structured screening is far from being a must in nearly all countries, vision can be improved but not yet restored ... the list could go on.

As a little homage to the 25th anniversary of EASDec, we have collected all material from previous annual meetings: scientific programmes, board composition at different times, etc. You can see that all in our website: www.easdec.org. Anybody with any material that could fill the remaining gaps, particularly those relevant to the first years of activity, please let us have them.

We received a record number of free communications this year. Most of them were of excellent quality and the Scientific Board made all possible efforts to give each of them right prominence within the programme, either as oral or poster presentations. A little guide to interpreting scientific conferences is also included in this booklet, a light contribution that I hope will not apply too literally to our meeting!

Finally, I wish to give special thanks to the EASDec team, which I had the honour of leading these past three years: Tunde Peto, Simon Harding, Rafael Simò and Reinier Schlingemann. Thanks are due to the sponsors, without whom the meeting would definitely have other dimensions, and to Mrs. Bersezio and her friendly team in the Organising Secretariat. Not only I hope that you will enjoy the scientific and social programme. Being fully aware of their capabilities, I am sure it cannot be otherwise!

Massimo Porta

President of EASDec and Chairman of the Local Organising Committee

EASDec - EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES Eye Complications Study Group (EASDec)

EASDec is a Study Group of the European Association for the Study of Diabetes (EASD) with special responsibility for the study of the eye complications of diabetes.

Its aim is to promote the advancement of knowledge of all aspects of diabetic retinopathy, including epidemiology, pathology, pathophysiology, investigation and treatment through active collaboration between ophthalmologists and diabetologists.

The ultimate goal of the Group is to prevent the development of diabetic retinopathy and to search for the best treatment of this condition in diabetic patients.

EASDec Board

Professor **Massimo Porta**, Turin, Italy - President

Professor **Simon Harding**, Liverpool, UK - President Elect

Professor **Rafael Simò**, Barcelona, Spain - Treasurer

Professor **Tunde Peto**, London, UK - Secretary

Professor **Reiner O. Schlingemann**, Amsterdam, NL - Adjunct

SCIENTIFIC PROGRAMME

EASDec 2015

European Association for the study of Diabetes
Eye Complication Study Group (EASDec)



26TH JUNE 2015, FRIDAY

Symposium 1

Diabetic retinopathy: from treating diabetes mellitus to diabetic eye screening

Chair: Professor Ugo Menchini

- 14.00** Welcome and introduction from Chairs
- 14.15** Focus on patients: key characteristics and common comorbidities in patients affected by DME and DR
Edoardo Mannucci
- 15.05** Two years results from an Italian diabetic retinopathy screening programme
Francesco Boscia
- 15.20** Ranibizumab in DME: optimizing clinical outcomes with a flexible and customized approach
Massimo Nicolò
- 15.35** Breakthrough therapy: disease modifying effect of Ranibizumab in DR
Federico Ricci
- 15.50** Panel Q & A and closing comments
Ugo Menchini

Symposium 2


Automated image analysis: relieving the burden of screening for diabetic retinopathy

Chair: Professor Reiner Schlingemann

- 16.30** Welcome and introduction from Chair
- 16.35** Screening for diabetic retinopathy: background and challenges
Simon Harding
- 17.00** Successful recent screening initiatives: Italy
Massimo Porta
- 17.15** Successful recent screening initiatives: France
Ali Erginay
- 17.30** Retinopathy screening in the Diabetes Care System West-Friesland, test characteristics of an automatic risk screening
Giel Nijpels
- 17.45** Automated screening for diabetic retinopathy: state of the art
Tunde Peto
- 18.15** Panel Q & A and closing comments

The official programme of EASDec starts

- 19.00** Opening ceremony followed by refreshments
Opened by: Professor Massimo Porta



08.30 Registration

09.00 Introduction and welcome
Professor Massimo Porta

SESSION 1: EPIDEMIOLOGY AND CLINICAL MANAGEMENT OF DIABETES AND DIABETIC RETINOPATHY

Chairs: Professors Simon Harding and Federico Grignolo

09.15 Patient perspectives of acceptability of risk-based individualised diabetic retinopathy
P. Byrne, C. Thetford, M. Gabbay, A. Wang, D. Broadbent, S.P. Harding (United Kingdom)

09.30 Diabetic retinopathy in Europe initial results of the E3 Consortium Diabetes Group
M. Hansen, T. Coolen, T. Peto (United Kingdom, Denmark)

09.45 Incidence and progression of retinopathy and visual impairment in people with diabetes in Sub-Saharan Africa: relationship with population specific variables
P. Burgess, T.J. Allain, G. Msukwa, C. Pindani, O. Mkangadzula, M. Garcia-Finana, S.P. Harding (United Kingdom, Malawi)

10.00 Registry study of diabetic macular edema in Turkey: Turk-dem study
S. Kadayifcilar (Turkey)

10.15 KEYNOTE SPEAKER:
Professor Stefano Del Prato
Implementing patient-centred approach for treatment of Type 2 diabetes?
Introduced by Professor Massimo Porta

11.00 Coffee / tea, exhibitions

SESSION 2: EXPERIMENTAL AND LABORATORY STUDIES OF DIABETIC RETINOPATHY

Chairs: Professors Rafael Simo and Massimo Porta

11.25 Inhibition of protein tyrosine phosphatase 1B improves IGF-I receptor signalling and protects against inflammation-induced gliosis in the retina
A.M. Valverde, A.I. Arroba (Spain)

11.40 Down-regulation of MIR-126 in human retinal pericytes after exposure to extracellular vesicles in diabetic-like conditions
A. Mazzeo, E. Beltramo, A. Iavello, S. Grimaldi, A. Carpanetto, M. Porta (Italy)

11.55 The regulation of retinal arteriolar diameters in diabetic patients involves NO and COX products
L. Petersen, T. Bek (Denmark)

12.10 Hypoxia and hyperglycaemia-induced pericyte apoptosis: identification of pro-apoptotic markers
E. Beltramo, A.I. Arroba, A. Mazzeo, M. Porta, A.M. Valverde (Italy)

12.25 Modulation of camp signalling prevents tnfa-induced Endothelial Barrier Disruption in an In Vitro Model of the Blood-Retinal Barrier
A. Van Der Wijk, C.J.F. Van Noorden, I. Klaassen, R.O. Schlingemann (The Netherlands)

12.40 Adipose-derived stromal cells contribute to microvascular stabilization in diabetic proliferative retinopathy: to be or notch to be?
V. Terlizzi, H.P. Hammes, M.C. Harmsen (The Netherlands)



LUNCH, EXHIBITION VIEWING, POSTERS AND COFFEE/TEA

13.00 Lunch (poster presenters' priority)

13.30 Poster presenters at poster - moderators will visit


14.30 Poster presenters circulate -Tea/coffee served

SESSION 3: POSTER SESSION

Moderators: Professors Rafael Simo and Dr. Elena Beltramo, Professors Simon Harding and Sehnaz Karadeniz, Professor Reiner Schlingemann and Ingeborg Klaasen, Professors Massimo Porta and Tunde Peto, Associate Professor Steve Aldington and Dr. Philip Burgess

EXPERIMENTAL LABORATORY SCIENCE

- 1. The correlation between aqueous and serum level of Apolipoprotein A1 and B and diabetic retinopathy**
I. Timur, K. Ornek, O. Caglayan (Turkey)
- 2. Aqueous humor and serum levels of Nitric Oxide, malondialdehyde and total antioxidant status in diabetic and nondiabetic senile cataract patients**
A. Karalezli, S. Kulaksizoglu (Turkey)
- 3. Immunolocalisation of tubulin polymerisation promoter protein/p25 in the diabetic retina**
R. Tripon, L. Csincsik, J. Olah, J. Ovadi, I. Lengyel (Romania)
- 4. Benfotiamine prevents experimental diabetic retinopathy through regulation of endothelial angiopoietin-2 and protein GlcNAc modification**
Y. Feng, D. Zhao, K. Altvater, A. Hegen, U. Fiedler, T. Wieland, H.P. Hammes (Germany)
- 5. The role of lipoprotein phospholipase A2 in pathogenesis of diabetic retinopathy**
P. Canning, V. Prise, V. Wong, K. McAllister, P. Adamson, A.W. Stitt (UK)
- 6. Retinal gene expression shows compartment specific differences in health and disease**
C. Weinold, M. Kolibabka, G. Molema, D. Margerie, H. Hammes (The Netherlands)
- 7. Hyperglycemic memory - mechanisms relevant to the diabetic retina**
P. Friedrichs, A. Dietrich, G. Molema, H.P. Hammes (Germany)
- 8. MicroRNA signature in diabetic retinopathy**
J. Friedrich, C. Sticht, H. Hammes, G. Krenning (Germany)
- 9. Ocular distribution of fenofibrate and its active metabolite fenofibric acid after ocular and oral administration in rabbits**
K. Hoffman, H. Teunissen, P. Aubonnet, C. Foucher, H. Dinter, L. Huang, M. Salvador-Silva, J. Cook, O. Lacombe (Germany)
- 10. Intravitreal delivery of IgG aggregates induces immune cell activation in the healthy retina**
C. McVicar, D. Solomon, A. Stitt (UK)
- 11. Modulation of microglia polarity is a new target against Diabetic Retinopathy: an experimental approach in db/db mice**
A.I. Arroba, D. Cazoni, P. Bogdanov, M. García-Ramírez, C. Hernández, R. Simó, A.M. Valverde (Spain)
- 12. Mechanisms of action of calcium dobesilate in the early stages of diabetic retinopathy**
C. Hernández, P. Bogdanov, C. Solà, L. Corraliza, R. Simó (Spain)



13. ADSC therapy for treatment of diabetic retinopathy: the best or last resource?

G. Hajmoussa, A. Elorza, M. Harmsen (Netherlands)

14. Fetal metabolic reprogramming: Fetal placental gestational diabetes mellitus vascular progenitor cells resemble adult Type 2 proliferative diabetic retinopathy

R. Samuel, C. Premkumar, S. Rajendran, K. Ramanathan, S. Benjamin, J. Mathews, M. Seshadri (India)

EARLY RETINOPATHY

15. Vasoreparative potential of a unique population of stromal stem cells (SSCS) in ischaemic retina

V. Wong, L. Allen, R. Medina, S. Elliman, P. Loftus, L. O'Flynn, A.W. Stitt (UK)

16. Functional evaluation of the retina using multifocal electroretinography in the early stages of diabetic eye disease in the setting of a multicenter clinical trial

S. Simão (Portugal)

17. Inner retinal layer changes in diabetes mellitus Type 1 without clinical diabetic retinopathy

F. Akay, S. Toyran, E. Çağiltay (Turkey)

IMAGING

18. Retinal vascular geometry and its association to 16-year development of microvascular complications in patients with type 1 diabetes

M.L. Rasmussen, R. Broe, U. Frydkjaer-Olsen, T. Peto, J. Grauslund (Denmark)

19. Assessment of corneal epithelial thickness in diabetes mellitus patients

E. Turan-Vural, M. Yenerel, S. Imamoglu, N.Y. Ercalik, H.E. Yildiz, E.T. Kumral, A.F. Nohutcu (Turkey)

20. Diabetic retinopathy with a picture of Leber's hereditary microaneurysms

F. Yulek, N. Ugurlu, B. Polat, H.B. Baser, R. Ersoy, B. Cakir (Turkey)

GRADING

21. Intra- and intergrader reliability of semiautomatic measurements of fundus fluorescein angiography leakage in proliferative diabetic retinopathy

T. Torp, U. Frydkjaer-Olsen, R. Hansen, T. Peto, J. Grauslund (Denmark)

22. Real-world workflow effects of automated diabetic retinopathy screening in a primary diabetes care setting with the IDx-DR device

G. Nijpels, M. Abramoff, M. Niemeijer, E. Talmage, A. Van Der Heijden (The Netherlands)

23. Using both Optos wide-field and standard Topcon 7-field images in a clinical trial setting: advantages and challenges

T. Mansour, M. Michaelides, T. Peto (UK)

SCREENING

24. Introducing personalised risk based intervals in screening for diabetic retinopathy: the ISDR study

D. Broadbent, S. Harding, M. García-Fiñana, A. Fisher, A. Bennett, D. Appelbe, A. Wang (UK)

25. Barriers and motivators for attendance at diabetic retinopathy screening


J. Mackenzie, S. Aldington, P. Scanlon (UK)

26. Four years results of diabetic retinopathy screening system in Institute for clinical and experimental medicine in Prague

T. Sosna, M. Kahle, R. Pekna (Czech Republic)

27. A baseline situation analysis of diabetic retinopathy (DR) services (DRS) in 11 Commonwealth countries

P. Blows, M. Zondervan, C. Walker, A. Foster, T. Peto (UK)



- 28. Prevalence of diabetic retinopathy and its risk factors in the PAMDI population of the Mediterranean basin**
R. Piermarocchi, S. Piermarocchi, D. Tognetto, D. Florea, N. Shah, T. Peto (Italy)
- 29. The structure of disability in patients with ocular complications of diabetes and the organisation of care**
S. Djamalova, S. Iskandarova, A. Nabiev (Uzbekistan)
- 30. Prevalence of Diabetic Retinopathy in New Onset Diabetes after Kidney and Liver Transplantation**
A. Hamid, S.G. Golar, H.W. Wharton, P.D. Dodson, A.W. Wright (UK)
- 31. The effects of obesity, diabetic regulation, hyperlipidemia and insulin preparations on diabetic retinopathy**
L. Balyen, L. Balyen, S. Pasa, O. Satici (Turkey)
- 32. The relation between open-angle glaucoma and the severity of diabetic retinopathy: A single center experience**
O. Satici, L. Balyen, L. Balyen, S. Pasa (Turkey)
- 33. Evaluation of sexual dysfunction in patients with type 2 diabetes**
D. Gokalp, L. Balyen, L.S.D. Balyen, S. Pasa, O. Satici (Turkey)
- 34. Does diabetes worsen MacTel?**
D. Florea, T. Mansour, I. Leung, T. Clemons, T. Peto (UK)
- 35. The Prevalence and Risk factors of Diabetic Macular Edema: A Cross-Sectional Study in Turkey**
D. Acan, M. Calan, D. Er, T. Arkan, N. Kocak, F. Bayraktar, S. Kaynak (Turkey)
- 36. Baseline characteristics of diabetic macular edema patients from the second interim analysis of the real-world LUMINOUS study**
A. Minnella (Italy)

CLINICAL MANAGEMENT OF DME

- 37. The comparison of short term effectiveness of grid laser photocoagulation, intravitreal triamcinolone acetonide and intravitreal bevacizumab in diffuse diabetic macular edema**
Y. Aksoy, A. Ayata, K. Çolakoğlu, M. Sönmez, M.H. Unal (Turkey)
- 38. Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment?**
E. Turkoglu, E. Celik, N. Aksoy, O. Bursalı, G. Alagoz (Turkey)
- 39. Case series evaluating intravitreal fluocinolone implant (ILUVIEN®; [FAC]) in the treatment of patients with chronic diabetic macular edema (DME) insufficiently responsive to current treatment options**
T. Patel, C. Goldsmith (TP and CG are joint first authors), M. Raja (UK)
- 40. Anatomical and functional results after different treatment modalities in serous macular detachment accompanying diabetic macular edema - withdrawn -**
D. Güven, S. Çınar, M. Demir, S. Ü. Uzun, A.M. Yıldız, Y. Baraç (Turkey)
- 41. Ranibizumab treatment for diabetic macular oedema (DMO): Initial response and NICE compliance**
S. Hassan, S. Mann (UK)
- 42. Comparison of effects of intravitreal versus posterior subtenon triamcinolone acetonide injection on intraocular pressure in patients with diabetic macular edema**
A. Atay, L. Balyen, L. Balyen, S. Pasa, O. Satici (Turkey)
- 43. Intravitreal ranibizumab for macular edema in patients with different diabetic retinopathy severity**
H. Güçlü, S.A. Özal, V.P. Gürlü (Turkey)
- 44. Combined intravitreal ranibizumab and posterior sub-Tenon injection of triamcinolone acetonide for the treatment of diabetic macular edema with serous retinal detachment**
N.Y. Erçalık, N.M. Yenerel, S. İmamoğlu, E.T. Kumral, E.T. Vural (Turkey)



- 45. The Efficiency of Dexamethasone intravitreal implant in the treatment of macular edema secondary to diabetes mellitus**
E. Unsal, K. Eltutar, P. Sultan, S.O. Erkul (Turkey)
- 46. Effectiveness of a single subtenon triamcinolone acetonide injection on macular thickness evaluated by optical coherence tomography in diabetic patients after cataract surgery**
M. Yorgun, Y. Toklu, H. Cakmak, D. Dal, N. Cagil (Turkey)
- 47. Intravitreal ranibizumab injection for diffuse diabetic macular edema unresponsive to modified grid laser photocoagulation**
B. Cakir, E. Celik, E. Dogan, E. Turkoglu, G. Erdogan, G. Alagoz (Turkey)
- 48. Comparison of modified grid laser photocoagulation and intravitreal ranibizumab injection for diffuse diabetic macular edema**
E. Celik, B. Caki, E. Turkoglu, E. Dogan, G. Erdogan, G. Alagoz (Turkey)
- 49. Anti-Vascular Endothelial Growth Factor for a Complication of Panretinal Photocoagulation in Proliferative Diabetic Retinopathy**
A. Kukner, Z. Sarman, N. Yis, S. Selim, I. Kocamis (Turkey)
- 50. Morphologic and functional modifications after anti-VEGF treatment in center involving diabetic macular edema**
S. Vujosevic, M. Berton, S. Bini, E. Convento, F. Martini, E. Midena (Italy)
- 51. Short term follow-up of retinal nerve fibre layer alteration after grid laser photocoagulation**
M. Bulut, D. Çelik, Ü. Çallı, K.T. Bulut, Y. Özertürk (Turkey)

CLINICAL MANAGEMENT

- 52. Outcome of vitreoretinal surgery in cases with diabetic and idiopathic vitreomacular traction syndrome**
M.M. Uzel, M. Çitirık, Ç. İlhan, M.Y. Teke (Turkey)
- 53. The vitreomacular interface following intravitreal injections of ranibizumab in patients with central involving diabetic macular edema - withdrawn -**
N. Lois, M. Mikhail, R. Hogg, (UK)
- 54. Treatment of diabetic macular edema with pars plana vitrectomy, peeling of internal limiting membrane and additional triamcinolone and laser coagulation**
J. Stefanickova, V. Krasnik, K. Vavrova, P. Strmen (Slovakia)
- 55. Evaluation of a joint Ophthalmology/Diabetes Nurse Specialist clinic to support patients with sight threatening diabetic retinopathy**
M. Morgan, K. Crerand (Ireland)
- 56. Presence of Diabetes Mellitus on Corneal Thickness Recovery after Uncomplicated Phacoemulsification Surgery**
A.K. Altintas, K. Tekin, V. Cankurtaran (Turkey)
- 57. The Corneal Biomechanical Parameters in Type 1 Diabetes Mellitus**
S. Dikci, O. Genc, R. Ekmen, M. Tas, P.G. Firat, S. Demirel (Turkey)
- 58. Pupil size before and after phacoemulsification in healthy, diabetic and systemic arterial hypertension patients by Combined Scheimpflug-Placido Disk Topographer**
A. Şimşek, Ş. Bilak, B. Bilgin, L. Balyen, M. Çapkın, A. Şahin (Turkey)
- 59. The fixed combination of efficacy assessment in patients with secondary neovascular glaucoma and diabetes mellitus**
D. Lipatov, T. Chistyakov, A. Kuzmin, A. Tolkacheva (Russia)
- 60. The association between metabolic regulation of patients with diabetes and phacoemulsification intraoperative and postoperative complications**
L. Balyen (Turkey)



SESSION 4: AUTOMATED GRADING: REAL LIFE EXPERIENCE


Chairs: Professors Deborah Broadbent and Paolo Prinetto

- 15.00** Screening for Diabetic Retinopathy in the Central Region of Portugal. Added value of automated “disease / no disease” grading
M.L. Ribeiro, C.M. Oliveira, C. Neves, D. Ramos, H. Ferreira, J. Cunha-Vaz (Portugal)
- 15.15** Automated high-throughput screening of diabetic retinopathy is safe and effective
K. Solanki, M. Bhaskaranand, S. Bhat, C. Ramachandra (USA)
- 15.30** Comparison of Screening for Diabetic Retinopathy between Clinical Examination by Ophthalmologists and Automated Detection from Retinal Colour Images
M. Abramoff, J.C. Folk, E. Daniel, M. Maguire (USA)
- 15.45** The application of machine learning to the automated detection of microaneurysms in different ethnic groups with diabetic retinopathy
T. Peto, G.M. Saleh, Silvestro Caputo, Lutfiah Ismail Al Turk, Su Wang, Yin Hu, Hongying Lilian Tang (UK)

DIABETIC MACULAR EDEMA (OR IS IT OEDEMA?)

- 16.15** In favour of OCT guided therapy using intravitreal injections
Dr. Stela Vujosevic
- 16.30** In favour of FFA-guided therapy and laser
Professor Reinier Schlingemann
- 16.45** Discussion
- 17.00** Annual General Meeting
Moderator: Tunde Peto

GALA DINNER: 19.30 PM MEETING FOR 20.00 PM DINNER



Albert Einstein

It is a miracle that curiosity survives formal education.

SESSION 5: THE ROLE OF EARLY NEURODEGENERATION IN DIABETIC EYE DISEASE

Chairs: Professors Reiner Schlingemann and Jose Cunha-Vaz

- 09.00** Neuro - Degeneration of Cornea and Retina in patients with Type 1 diabetes without Clinical evidence of diabetic Retinopathy and Neuropathy
M. Tavakoli, M. Ferdousi, I. Petropoulos, H. Fadavi, A.J.M. Boulton, R. Malik (UK)
- 09.15** To evaluate the choroidal thickness in type 2 diabetic patients with or without diabetic polyneuropathy
Yazici, A (Turkey)
- 09.30** Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes
R. Simó, P. Bogdanov, L. Corraliza, M. García-Ramírez, A.I. Arroba, A.M. Valverde, C. Hernández (Spain)
- 09.45** The Correlation Between Retinal Vascular Fractals and Neurodegeneration in Patients with Type 2 Diabetes Mellitus
U. Frydkjaer-Olsen, R.S. Hansen, K. Pedersen, J. Cunha-Vaz, R. Simó, T. Peto, J. Grauslund (Denmark)
- 10.00** Correspondence between central mfERG changes and Thinning of Ganglion Cells and Retinal Nerve Fiber layers in the initial stages of Diabetic Retinopathy
A.R. Santos (Portugal)
- 10.15** **EVA KOHNER LECTURE**
Professor Peter Scanlon
Diabetic retinopathy and DME/DMO endpoints and outcome measures in clinics, trials and studies
Introduced by Professor Massimo Porta
- 11.00** Coffee Break

SESSION 6: CLINICAL INVESTIGATIONS IN DIABETIC RETINOPATHY

Chairs: Professors Tunde Peto and Ugo Menchini

- 11.30** The winner of Anne-Katrin Sjolie Best Young Investigator Prize:
Retinal layer location of increased retinal thickness in eyes with subclinical and clinical macular edema in diabetes type 2
C. Neves (Portugal)
- 11.45** Individualised risk-based screening for diabetic retinopathy - the Liverpool risk calculation engine
S.P. Harding, A. Eleuteri, D.M. Broadbent, M. Van Der Hoek, C.P. Cheyne, I.M. Stratton, A.C. Fisher (UK)
- 12.00** Validation of a risk stratification algorithm for progression to referable diabetic retinopathy
S. Aldington, I.M. Stratton, T. Gazis, S. Sivaprasad, G. Russell, P.H. Scanlon (UK)
- 12.15** Cost-effectiveness of a risk-based screening programme for diabetic retinopathy: a modelling approach
C. Sampson, M. James, A.C. Fisher, S.P. Harding (UK)
- 12.30** Cognitive function may be a predictor of retinopathy progression in patients with type 2 diabetes
L. Borio, M. Salassa, A. Baltatescu, L. Charrier, F. Cavallo, M. Porta, M. Trento (Italy)
- 12.45** Evaluation of depression in type 2 diabetic patients with retinopathy
L. Balyen, L.S.D. Balyen, S. Pasa, O. Satıcı (Turkey)
- 13.00** **BEST POSTER PRIZE CEREMONY AND CLOSING REMARKS** by Professor Simon Harding
- 13.30** Farewell refreshment



LOCATIONS

SCIENTIFIC SESSIONS

Cavallerizza Reale

Via Giuseppe Verdi 9, Torino

SOCIAL EVENTS

WELCOME COCKTAIL

FRIDAY 26TH JUNE - H. 19.00

Aula Magna Cavallerizza Reale

Via Giuseppe Verdi 9, Torino


GALA DINNER

SATURDAY 27TH JUNE - H. 20.00

Circolo Eridano


Corso Moncalieri 88 - Torino







Science For A Better Life



Innovation and responsibility, at the patient's service

Global leader in the healthcare industry, Novartis is strongly committed to the research and development of drugs and innovative solutions to treat diseases, reduce the burden of pain and suffering and improve people's quality of life. With the primary goal of satisfying the needs of patients, by meeting the expectations and respecting the rights of all its

stakeholders, Novartis does its best to manage its activities in a sustainable way from a social, environmental and economic point of view. Thanks to its constant focus on innovation and its responsible approach to health requirements and needs, Novartis is a reliable reference point for millions of people, in Italy and all over the world.



LOCAL SCIENTIFIC COMMITTEE

Professor Massimo Porta
Dr. Elena Beltramo
Dr. Lorenzo Borio
Dr. Aurora Mazzeo
Dr. Marina Trento

Department of Medical Sciences, University of Turin
Corso Achille Mario Dogliotti 14, 10126 - Turin, Italy

LOCAL ORGANIZING SECRETARIAT

e-belf di Elisabetta Bersezio e C s.a.s.
C.so Regina Margherita 89, 10124 - Turin
Phone: + 39 011 4548142
www.e-belf.it

NOTES

[illegible]



A photograph of the Manchester Town Hall, a large, ornate Gothic Revival building with a prominent clock tower. The building is made of light-colored stone and features many arched windows and decorative carvings. In the foreground, there are bare trees and a statue on a pedestal. The sky is blue with some light clouds. A yellow banner is at the top right, and a dark blue banner is at the bottom left.

SEE YOU IN MANCHESTER

Arrivederci!

EASDec 2016



Under the patronage of



Università degli Studi di Torino
Dipartimento di Scienze Mediche



Scuola di Medicina